Back to search results

UPRISE Trial: Urine Test and MRI for Prostate Cancer Detection

This study, called the UPRISE Trial, is looking at how well a urine test called My Prostate Score 2 (MPS2) combined with an MRI (Magnetic Resonance Imaging) can find prostate cancer early. MPS2 is a new urine test that measures genetic information to help predict the chance of having aggressive prostate cancer. The goal is to find only the cancers that truly need treatment. You may be able to join if you are a man between 50 and 75 years old, have a PSA (prostate-specific antigen) level between 3-20 ng/ml, and have not had a prostate biopsy in the last 4 years or an MRI in the last 2 years. The study will measure if these methods can accurately detect clinically significant prostate cancer.

Study design
This is an interventional study planning to enroll 800 male participants. It is testing a urine test (MPS2) and MRI for prostate cancer detection.
What's involved
Participants will undergo a biopsy procedure, an MPS2 urine test, and an MRI. There will also be a review of your electronic health records.
Compensation
Not stated in the trial record.
Follow-up
The primary outcome, clinically significant prostate cancer, will be measured up to 120 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07526545

Urine Prostate Screening Integrated With MRI for Early Detection of Prostate Cancer, UPRISE Trial

Not Yet Recruiting
NAAges 50–75InterventionalScreening
University of Michigan Rogel Cancer Center
~800 participants
Updated 2026-06-09 on ClinicalTrials.gov
What's tested:Biopsy ProcedureDiagnostic ProcedureElectronic Health Record ReviewMagnetic Resonance Imaging

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Clinically significant prostate cancer (csPCa), defined as Gleason Grade (GG) Group 2-5
Measured over Up to 120 days

Conditions

Prostate Carcinoma

Explore related trials

Prostate Carcinoma

Where it's being run

1 sites across 1 states
Michigan1

Study leadership

  • Udit Singhal, MD · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center
  • Todd Morgan, MD · PRINCIPAL_INVESTIGATOR · University of Michigan Rogel Cancer Center

Who to contact

Uprise StudyTeam
[email protected]
734-615-6662
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Males aged 50-75
PSA 3-20 ng/ml within the previous 3 months
Fit to undergo all procedures listed in protocol per treating physician's discretion
No prostate biopsy in the past 4 years
No prostate MRI in the past 2 years
Able to provide written informed consent

Exclusion

Prior diagnosis of prostate cancer
Contraindication to MRI (e.g. claustrophobia, pacemaker)
Contraindication to prostate biopsy
Previous hip replacement surgery, metallic hip replacement or extensive pelvic orthopaedic metal work

What this trial measures

  • Clinically significant prostate cancer (csPCa), defined as Gleason Grade (GG) Group 2-5Up to 120 days

    Will compare the proportions of patients with detected csPCa in the intervention and control arms (p1 and p2, respectively) using the OBrien Fleming stopping boundaries which control the overall one-sided Type I error rate to be less than .10.